(Q36977560)

17 August 2017

1 reference

title

Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant (English)

1 reference

17 August 2017

1 reference

Shaw BE

1

1 reference

17 August 2017

Russell NH

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

22 October 2007

1 reference

Bone Marrow Transplantation

17 August 2017

1 reference

17 August 2017

41

1 reference

17 August 2017

5

1 reference

17 August 2017

495-503

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705888

17 August 2017

0 references

cites work

Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

How and when should we monitor chimerism after allogeneic stem cell transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-fr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripher

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Donor leukocyte infusions in myeloid malignancies: new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

Leukemia: management of relapse after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705888

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705888

1 reference

Dimensions Publication ID

17 August 2017

0 references

1 reference